Literature DB >> 9588486

Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats.

J C Woodson1, T R Minor, R F Job.   

Abstract

Three experiments examined the role of adenosine neuroregulation in the production of shuttle-escape deficits caused by prior exposure to inescapable electric shock in rats (learned helplessness). Intracerebroventricular administration of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), a selective adenosine deaminase inhibitor, mimicked the effect of earlier inescapable shock at a dose of 2.5 microM in previously restrained rats. Performance deficits produced by EHNA or by earlier exposure to inescapable shock were reversed by intraperitoneal injection of 10 mg/kg caffeine, an adenosine receptor antagonist. Finally, preexposure to an ineffective number of shocks interacted in synergy with an ineffective pretest dose (1.0 microM) of EHNA to maximize shuttle-escape latencies. These data implicate endogenous adenosine neuroregulation as a proximate mechanism in learned helplessness and conservation-withdrawal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588486     DOI: 10.1037//0735-7044.112.2.399

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  14 in total

Review 1.  The effects of uncontrollable, unpredictable aversive and appetitive events: similar effects warrant similar, but not identical, explanations?

Authors:  R F Soames Job
Journal:  Integr Physiol Behav Sci       Date:  2002 Jan-Mar

2.  Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.

Authors:  M El Yacoubi; C Ledent; M Parmentier; R Bertorelli; E Ongini; J Costentin; J M Vaugeois
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.

Authors:  Koji Yamada; Minoru Kobayashi; Shizuo Shiozaki; Teruko Ohta; Akihisa Mori; Peter Jenner; Tomoyuki Kanda
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

Review 4.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

Review 5.  Cytokine-purine interactions in behavioral depression in rats.

Authors:  Thomas R Minor; Qingjun Huang; Elizabeth A Foley
Journal:  Integr Physiol Behav Sci       Date:  2003 Jul-Sep

6.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

7.  Psychological factors in asthma.

Authors:  Ryan J Van Lieshout; Glenda Macqueen
Journal:  Allergy Asthma Clin Immunol       Date:  2008-03-15       Impact factor: 3.406

Review 8.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Wheel running alters patterns of uncontrollable stress-induced cfos mRNA expression in rat dorsal striatum direct and indirect pathways: A possible role for plasticity in adenosine receptors.

Authors:  Peter J Clark; Parsa R Ghasem; Agnieszka Mika; Heidi E Day; Jonathan J Herrera; Benjamin N Greenwood; Monika Fleshner
Journal:  Behav Brain Res       Date:  2014-07-11       Impact factor: 3.332

Review 10.  Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems.

Authors:  László Köles; Erzsébet Kató; Adrienn Hanuska; Zoltán S Zádori; Mahmoud Al-Khrasani; Tibor Zelles; Patrizia Rubini; Peter Illes
Journal:  Purinergic Signal       Date:  2015-11-06       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.